Research priorities should include: dynamic changes in pathway activity in different molecular subtypes (Luminal A/B), how tumor-stromal cell crosstalk affects pathway function, developing combination therapies based on pathway status such as sequential STING agonist and immune checkpoint inhibitor or AKT inhibitor use. Here, AKT1 is linked to neoplasm.